argenx to buy Forte Biosciences for USD 77 per share in cash, valuing deal at USD 2.2 billion
FBRX•Lead asset FB102 included in the transaction
The deal adds lead asset FB102, a first-in-class anti-CD122 antibody with Phase 1b readouts in vitiligo and celiac disease.
The transaction is expected to close in Q3 2026. Funding is expected to come from argenx cash on hand.
argenx agrees to all-cash acquisition of Forte Biosciences
argenx agreed to buy Forte Biosciences in an all-cash deal priced at USD 77 per share, valuing equity at about USD 2.2 billion.
The price implies an 86% premium to Forte’s VWAP since reporting positive Phase 1b vitiligo data on July 9, 2026.
